“Insured individuals will have more reimbursable drugs for psoriasis, systemic lupus erythematosus and other conditions”
The Reimbursable Drug Council has decided to increase access to reimbursable medications for insured individuals with psoriasis and systemic lupus erythematosus. With the new changes, five international generic drug names for psoriasis will be fully reimbursed for long-term treatment, and four will be partially reimbursed for episodic outpatient treatment. Also, insured persons with systemic lupus erythematosus will have access to episodic outpatient treatment with three generic drugs from the group of non-steroidal anti-inflammatory drugs.
The list of compensated drugs will also be expanded with new drugs for the long-term treatment of glaucoma. Three common international names for eye drops will become fully reimbursed.
Also from August 1, adults and children receiving palliative care in outpatient settings will have free access to another medicine – ibuprofen.
The Board also decided to expand the indications for the drugs lercanidipine and dapagliflozin, which will make it possible to prescribe them to patients with cardiovascular diseases and diabetes mellitus.
These changes will also entail a recalculation of the fixed amounts reimbursed from the health insurance funds. This contributes to increasing the amount reimbursed by health insurance and reducing patients’ expenses.
It is planned that the cost of reimbursing new medicines is estimated at about 35 million lei (1.75 million euros) annually, according to the Ministry of Health.
